Zealand Pharma increases its share capital as a consequence of exercise of employee warrants


14.09.18 09:50
Meldung
 
<strong>Zealand Pharma</strong> increases its share capital as a consequence of exercise of employee warrants

Company announcement - No. 22 / 2018

Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Copenhagen, September 14, 2018 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 7,500 divided into 7,500 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand's warrant programs, see the company's Articles of Association, which are available on the website: www.zealandpharma.com.

The exercise price was DKK 101.20 per share and the total proceeds to Zealand from the capital increase amount to DKK 759,000.00.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 30,758,827 divided into 30,758,827 shares with a nominal value of DKK 1 each.

The amendment to Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand's current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand's portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

22-18_0914_announcement_capital increase_final






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

Zealand Pharma

Aktuelle Diskussionen zum Thema:

ZealandPharma, gute Ergebnisse ... (22.11.16)

Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Zealand Pharma
Weitere Meldungen
 
14.09 Zealand Pharma increases it.
14.09 Hoylu AB: HOYLU HIRES N.
14.09 EQS-Adhoc: AEVIS VICTOR.
13.09 Galapagos and MorphoSys a.
13.09 Ad hoc: Aufsichtsrat und V.
13.09 Ad hoc: Deutsche Industrie .
13.09 WISeKey Reports First Half.
13.09 Ad hoc: METRO AG: METR.
13.09 Ad hoc: VST BUILDING TE.
13.09 EQS-Adhoc: Jungfraubahn H.
13.09 Ad hoc: Deutsche Industrie .
13.09 SCOR in exclusive negotiatio.
13.09 FLOW TRADERS CO-CEO .
13.09 Ad hoc: SGL CARBON SE:.
13.09 Sanofi to refocus two globa.
13.09 Shareholders Approve DNO .
13.09 Roche zum zehnten Mal als .
13.09 Roche ranked the most sust.
13.09 Active Biotech: Data from t.
13.09 Ad hoc: Lumaland AG: Lum.
13.09 Wolters Kluwer N.V.: Share.
13.09 Ad hoc: SGL CARBON SE:.
13.09 Unibail-Rodamco-Westfield an.
13.09 Odfjell SE to present at Pa.
13.09 TGS announces new 3D mu.
13.09 Galapagos raises $300 millio.
12.09 Galapagos announces launch .
12.09 MorphoSys and Galapagos a.
12.09 Ad hoc: SHOPiMORE AG: a.
12.09 Ad hoc: M1 Kliniken AG: M.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 44918 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Lufthansa: Stoppt hier der Höhenflug?
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Gold - JETZT am ...
Philip Hopf, Hopf Klinkmüller Capital. (23.01.19)
Experte: Philip Hopf, Hopf Klinkmüller Capital Management K.
DOW DAX testet den ...
Thomas Heydrich, Systemstradings.de (23.01.19)
Experte: Thomas Heydrich, Systemstradings.de
Deutsche Bank: Boden ...
S. Feuerstein, Hebelzertifikate-Trader (23.01.19)
Experte: S. Feuerstein, Hebelzertifikate-Trader
DAX verteidigt 11.000er ...
CMC Markets, (23.01.19)
Experte: CMC Markets,
Der größte Reichtum ...
Volker Gelfarth, (23.01.19)
Experte: Volker Gelfarth,
ETFs: Der Hang zum ...
Redaktion boerse-frankf., Deutsche Börse AG (23.01.19)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
nach schwachem Start – ...
Cornelia Frey, Börse Stuttgart AG (23.01.19)
Experte: Cornelia Frey, Börse Stuttgart AG
S&P500 - Weiterhin ...
Christian Zoller, www.boerse-daily.de (23.01.19)
Experte: Christian Zoller, www.boerse-daily.de
Facebook – 11 Prozent für ...
Feingold-Research, (23.01.19)
Experte: Feingold-Research,
Nordex: „Erste Früchte“!
Robert Sasse, (23.01.19)
Experte: Robert Sasse,
Hat Facebook wirklich einen ...
Christian-Hendrik Knappe, Produktexperte X-marke. (23.01.19)
Experte: Christian-Hendrik Knappe, Produktexperte X-markets, Deutsche Ba.
Börsengeflüster: #SIG ...
WIRTSCHAFTSINFORM., (23.01.19)
Experte: WIRTSCHAFTSINFORMATION .,
Niquet's World
Neues vom Portal
 
Ressourcen-Steuerung: Neue Chancen für den Mittelstand?
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen